SIRT1 and metabolic dysfunction-associated steatotic liver disease: Moreover, activation of SIRT1 is protective against metabolic disorders known to affect patients with SBMA, such as nonalcoholic fatty liver disease (12, 75, 76), impaired glucose homeostasis (12, 13, 15, 36, 70), and mitochondrial dysfunction (35, 52, 65).